TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01088659
Drug: tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 245mg po daily, 96 weeks
Study: NCT00978172
Drug: artesunate and mefloquine
Normalized name: artesunate and mefloquine
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally
Study: NCT00006463
Drug: ECTEINASCIDIN 743
Normalized name: Ecteinascidin 743
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01296464
Drug: Carbidopa
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules
Study: NCT02181504
Drug: abicipar pegol
Normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
Study: NCT02181504
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
Study: NCT04569877
Drug: Molgramostim nebuliser solution
Normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300μg molgramostim nebuliser solution nebulised seven times within 7 days via rapid nebuliser system
Study: NCT00350025
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 250mg/m2 IV weekly for each 28 day cycle.
Study: NCT00350025
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.
Study: NCT00424645
Drug: Voraxaze (Glucarpidase)
Normalized name: Voraxaze
DrugBank: Glucarpidase (DB08898)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 units/kg IV within 12 hours of study eligibility being confirmed.
Study: NCT01487694
Drug: cimicifuga racemosa
Normalized name: CIMICIFUGA RACEMOSA ROOT
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifuga racemosa (black cohosh) rhizome and root extract 40 mg once daily for 12 weeks (equivalent to triterpene glycosides 12.3 mg)
Study: NCT00468624
Drug: pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00035828
Drug: ABX-IL8
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01604161
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
Study: NCT02779634
Drug: ubiquinol
Normalized name: Ubiquinol
DrugBank: Ubiquinol (DB11340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol three times daily
Study: NCT03707795
Drug: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given four IM injections throughout the study
Study: NCT01011998
Drug: Gleevec (imatinib), valproic acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid: 250 mg three times per day and then adjusted according to attain a therapeutic level.~Gleevec will be continued at the dose the patient was taking at the time of entry onto the study.
Study: NCT04221828
Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Normalized name: Nanoparticulate paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles. For clinical administration, the NanoPac powder in vial is suspended with Sterile Reconstitution Solution (1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP) and then further diluted with 0.9% Sodium Chloride for Injection, USP, to achieve the final clinical formulation.
Study: NCT00788034
Drug: Lu AA21004
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 10 mg/day
Study: NCT02555215
Drug: dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered orally
Study: NCT01595061
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01595061
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00457743
Drug: Sunitinib malate (SU011248)
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SU011248
Study: NCT02301208
Drug: Nedaplatin
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin combine with IMRT
Study: NCT02301208
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin combine with IMRT
Study: NCT02689141
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
Study: NCT02689141
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v.
Study: NCT02689141
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
Study: NCT00938184
Drug: Paroxetine 12.5 milligrams tablet
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of paroxetine 12.5 milligrams controlled release tablet will be administered orally.
Study: NCT00938184
Drug: Paroxetine 25 milligrams tablet
Normalized name: paroxetine hydrochloride 25 MG
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of paroxetine 25 milligrams controlled release tablet will be administered orally.
Study: NCT00938184
Drug: Paroxetine 50 milligrams tablet
Normalized name: Paroxetine Tablets
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of paroxetine 50 milligrams controlled release tablet (as two tablets of 25 milligrams) will be administered orally.
Study: NCT02012569
Drug: TT-173
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times for about 1 minute apart each application after skin graft obtention.
Study: NCT01736514
Drug: febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral
Study: NCT01736514
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01102231
Drug: ERBITUX
Normalized name: Erbitux
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
Study: NCT03903822
Drug: PF-06700841
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06700841 topical cream
Study: NCT03903822
Drug: Vehicle (Placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle topical cream
Study: NCT03529175
Drug: Abraxane (nab-paclitaxel)
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00416624
Drug: darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00416624
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03529175
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01198145
Drug: sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00785512
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
Study: NCT01668459
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6
Study: NCT01563406
Drug: 70% isopropyl alcohol
Normalized name: GNP 70% Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
Study: NCT00003804
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00648492
Drug: Metformin Hydrochloride ER Tablets 500 mg
Normalized name: metformin hydrochloride Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg, single dose fed
Study: NCT01893801
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
Study: NCT01893801
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle
Study: NCT01893801
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
Study: NCT02980991
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery
Study: NCT02980991
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
Study: NCT04143789
Drug: AP-002
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose escalation
Study: NCT00807118
Drug: Fesoterodine
Normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 2 x 4 mg tab in formulation F under fed condition
Study: NCT00807118
Drug: Fesoterodine
Normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 1 x 8 mg tab in formulation F under fed condition
Study: NCT00807118
Drug: Fesoterodine
Normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 1 x 8 mg tab in formulation E(1) under fed condition
Study: NCT00807118
Drug: Fesoterodine
Normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 2 x 4 mg tab in formulation F under fasted condition
Study: NCT00807118
Drug: Fesoterodine
Normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 1 x 8 mg tab in formulation F under fasted condition
Study: NCT00006062
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01095640
Drug: adapalene 0.3% topical gel
Normalized name: Adapalene 0.3% Topical gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once a day, 84 days
Study: NCT02718521
Drug: Visipaque
Normalized name: Visipaque
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
Study: NCT02718521
Drug: 0.9% sodium chloride ﬂuid administration
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02718521
Drug: isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03752138
Drug: Group 1: TK216
DrugBank: TK216 (DB17414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting Dose: 288 mg/m2 given by vein on Days 1-7 of a 21 day cycle.
Study: NCT03752138
Drug: Group 2: TK216
DrugBank: TK216 (DB17414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting Dose: 144 mg/m2 given by vein on Days 1-7 and 15-21 of a 23 day cycle.
Study: NCT03752138
Drug: Part 2: Decitabine 10mg/m2
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/m2 by vein on Days 1-10 of a 28 day cycle.
Study: NCT03752138
Drug: Part 2: Decitabine 20 mg/m2
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 by vein on Days 1-10 of a 28 dayi cycle.
Study: NCT03752138
Drug: Expansion Phase TK216
Normalized name: ethanol
DrugBank: TK216 (DB17414)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Expansion cohort will receive the RP2D of TK216
Study: NCT03752138
Drug: Expansion Phase Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Expansion cohort will receive the RP2D of Decitabine
Study: NCT03752138
Drug: Part 2: TK216
DrugBank: TK216 (DB17414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dose from Part 1.
Study: NCT02193776
Drug: PA-824
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02193776
Drug: bedaquiline
Normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT02193776
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02193776
Drug: pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02193776
Drug: isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02455921
Drug: neostigmine - atropine
Normalized name: atropine / neostigmine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy, safety and effect on cognitive and behavioural function
Study: NCT02455921
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Efficacy, safety and effect on cognitive and behavioural function
Study: NCT00454714
Drug: single dose Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of a single dose Sildenafil
Study: NCT00285896
Drug: Glucagon-like-peptide-1 (7-36) amide
Normalized name: Glucagon-like-peptide-1 (7-36) amide
DrugBank: GLP-1 (7-36) amide (DB19258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours
Study: NCT01993160
Drug: Fluorocholine (18F-FCH) Injection
Normalized name: (18F)-Fluoride
DrugBank: Fluorocholine F-18 (DB15887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)
Study: NCT02034773
Drug: CC-220
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-220 0.3mg will be administered once daily for 14 days
Study: NCT02034773
Drug: CC-220
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination
Study: NCT02034773
Drug: CC-220
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-220 0.3mg will be administered once daily for 28 days
Study: NCT00888693
Drug: ABT-288
Normalized name: ABT-288
DrugBank: ABT-288 (DB15192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm Description for details.
Study: NCT02904798
Drug: Polypodium Leucotomos
Normalized name: Polypodium leucotomos
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light
Study: NCT05638932
Drug: Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real world use of either IL6Ri (TCZ or SAR) or JAKi (BAR or TOF)
Study: NCT02034773
Drug: CC-220
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing
Study: NCT02034773
Drug: CC-220
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)
Study: NCT02034773
Drug: CC-220
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-220 1mg (once every 7 days for 28 days)
Study: NCT02034773
Drug: CC-220
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules
Study: NCT02115139
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
Study: NCT03395860
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: group A:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3 group B:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
Study: NCT04106180
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive GM-CSF 125μg/m2 daily for 14 consecutive days after completing SBRT treatment.
Study: NCT04106180
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Sintilimab 200 mg every 3 weeks up to 2 years after completing SBRT treatment.
Study: NCT01095939
Drug: Benazepril hydrochloride
Normalized name: Benazepril Hydrochloride
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
Study: NCT03149055
Drug: Isavuconazole
Normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.
Study: NCT03296917
Drug: PrEP-001
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A spray dried powder for intranasal administration formulated from an aqueous mixture of pre-gelatinized waxy maize starch and the drug substance delivered using a single dose nasal powder device.
Study: NCT03296917
Drug: G-004
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A spray dried pre-gelatinized waxy maize starch powder (G-001) in the single dose nasal powder device
Study: NCT01198197
Drug: NOP-1A
Normalized name: NOP-1A
DrugBank: NOP-1A (DB15208)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00807443
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp \& Dohme. A dose of 400 mg will be administered every 12 hours
Study: NCT01012037
Drug: linagliptin low dose
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patient to receive tablets containing low dose linagliptin twice daily
Study: NCT02232035
Drug: normal saline/diazepam at the active phase of labor
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
Study: NCT00451672
Drug: bromocriptine
Normalized name: Bromocriptine
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01012037
Drug: linagliptin medium dose
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patient to receive a tablet containing medium dose linagliptin once daily
Study: NCT02760615
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan tablets